AGAR174, Australia AMR Funded by Organism Susceptibility S. aureus n/a Website; 256 (national surveillance DoHA; some testing of E. coli annual and supportive clinical Klebsiella spp. periodic laboratories; funding (e.g. isolates; Enterobacter surveys; 30 public Eli Lilly surveys of spp. (annually) institutions (1985–2002) AMR patterns; S. pneumoniae and 4 private applicability of Enterococcus publications; laboratories typing spp. H. conference representing methods influenzae all Australian (periodically) ability to states and monitor AMR territories) in private facilities and primary care Australia Funded by Hospital Total hospital 3rd/4th n/a Website; – 115, 152 (national; 70 use DoHA; and ICU generation hospitals monitoring coordinated usage rates cephalosporins, aggregate including 41 by for 6 glycopeptides, data reported tertiary referral Australian antimicrobial to DoHA and or large Infection classes ACSQHC; private Control bimonthly representing Service, and and annual all states and reports; territories) Disease penicillin with consumption Control beta-lactamase reported as Branch inhibitor WHO defined combinations DDD/1000 OBD
AGAR174, 256 Australia (national laboratories; 30 public institutions and 4 private laboratories representing all Australian states and territories) AMR surveillance Funded by DoHA; some supportive funding (e.g. Eli Lilly (1985–2002) Organism Susceptibility testing of clinical isolates; surveys of AMR patterns; applicability of typing methods S. aureus E. coli Klebsiella spp. Enterobacter spp. (annually) S. pneumoniae Enterococcus spp. H. influenzae (periodically) n/a Website; annual and periodic surveys; publications; conference ability to monitor AMR in private facilities and primary care 115, 152 Australia (national; 70 hospitals including 41 tertiary referral or large private representing all states and territories) use monitoring Funded by DoHA; coordinated by Australian Infection Control Service, Disease Control Branch – Hospital Total hospital and ICU usage rates for 6 antimicrobial classes 3rd/4th generation cephalosporins, glycopeptides, and penicillin with beta-lactamase inhibitor combinations n/a Website; aggregate data reported to DoHA and ACSQHC; bimonthly and annual reports; consumption reported as WHO defined DDD/1000 OBD
National-surveillance-and-reporting-of-antimicrobial-resistance-and-antibiotic-usage-for-human-health-in-Australia.docx